STLNNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLNW
Starling Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.46+0.03 (+0.47%)
Close on Oct 19, 2026
- Market cap
- $665.58M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2019 to 2025
Operating margin
-7.2%−2.8 pts over 5 years
Net margin
-12.1%−4.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +27.8% | +25.8% | +21.8% | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -40.7% | 999.2% | |
| Return on assets | – | -43.6% | -35.9% | |
| Current ratio | 0.92 | 1.04 | 1.59 | |
| Debt to equity | – | 0.42 | -4.92 | |
| Net debt to EBITDA | – | -1.18× | -1.50× | |
| Interest coverage | – | -23.6× | -3.2× | |
| Capex to revenue | – | 0.6% | 0.6% | |
| Diluted shares | – | 59M | 92M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Starling Oncology generated $181.88M from operations and spent $29.95M on capital expenditure, dividends and share buybacks. 67% of that went back into the business.
Generated
$181.88M
Used
$29.95M
Capital expenditure$19.93M67%Dividends$00%Share buybacks$10.02M33%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-12.1%
×Asset turnover2.98×
×Equity multiplier-27.81×
=Return on equity, FY2025999.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -12.1% | 2.98× | -27.81× | 999.2% |
| FY2024 | -16.4% | 2.06× | 6.30× | -213.4% |
| FY2023 | -25.6% | 1.38× | 2.61× | -92.2% |
| FY2022 | 0.1% | 1.09× | 2.05× | 0.1% |
| FY2021 | -5.4% | 1.51× | 2.03× | -16.5% |
| FY2020 | -7.6% | 5.70× | 0.93× | -40.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$60.61M
- Cash generatingOperating cash flow above zero-$24.59M
- Return on assets improvedROA up on the prior year-30.9% → -35.1%
- Earnings backed by cashOperating cash flow above net income-$24.59M vs -$60.61M
- Less leverageLong-term debt to assets fell53.9% → 47.0%
- Better liquidityCurrent ratio rose2.15 → 1.59
- No dilutionShare count did not rise75M → 92M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose1.88 → 2.91